FDA approves first biosimilar to treat macular degeneration
The Food and Drug Administration Friday approved the first biosimilar to treat neovascular age-related macular degeneration, a leading cause of vision loss and blindness for seniors. The biosimilar (Byooviz) also was approved to treat fluid build-up following vein blockage in the retina and myopic choroidal neovascularization, a vision-threatening complication of nearsightedness.
“Continuing to grow the number of biosimilar approvals is a key part of our efforts to provide greater access to treatment options for patients, increase competition and potentially lower costs,” said Sarah Yim, M.D., who directs the Office of Therapeutic Biologics and Biosimilars in FDA’s Center for Drug Evaluation and Research.
Related News Articles
Headline
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…
Headline
Draeger Medical, Inc. is recalling its Carina Ventilators due to the presence of contaminants in the device’s airpath, which exceed acceptable levels if…
Headline
Crews are working to restore power and assess damage to a Pfizer plant in North Carolina that makes sterile injectables for U.S. hospitals after a tornado…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
The Consumer Financial Protection Bureau, Centers for Medicare & Medicaid Services, Department of Health and Human Services, and Department of the Treasury…
Headline
As urged by the AHA and its professional membership group the Association for Health Care Resource & Materials Management, the Food and Drug Administration…